Immunome, Inc. reported $13M of revenue over the trailing twelve months, +4.7% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $13M (to Q2 2026). Net income: −$254M, trailing twelve months to Q2 2026. Free cash flow: −$219M, trailing twelve months to Q2 2026. Operating margin: −1989%, trailing twelve months to Q3 2025.

IMNMImmunome, Inc.

Healthcare

$19.56+108% 1Y

$19.56

$9.7752 weeks$29.84

IMNM as reported

Immunome, Inc. reported $13M of revenue over the trailing twelve months, +4.7% on the year before. 8 reported series are charted on this page, each one as filed.

$13M

Revenue, trailing twelve months · to Q2 2026 · +4.7% against the twelve months before

Net income: −$254M
Net income · +20% year on year · trailing twelve months to Q2 2026
Free cash flow: −$219M
Free cash flow · +18% year on year · trailing twelve months to Q2 2026
Operating margin: −1989%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for IMNM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$13M	+4.7%	Q2 2026
Net income	−$254M	+20%	Q2 2026
EPS	−$2.53	−18%	Q2 2026
Operating margin	−1989%	n/a	Q3 2025
Net margin	−1895%	n/a	Q3 2025
ROE	−51%	n/a	Q2 2026
ROA	−47%	n/a	Q2 2026
Free cash flow	−$219M	+18%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.